A new class of diabetes drugs called SGLT2 inhibitors launched in the U.S. in 2013 are demonstrating they can effectively drive down blood sugar levels and even help users lose weight. But those benefits come at a risk, according to a speaker at the Cardiometabolic Health Congress. SGLT2 inhibitors, or sodium-glucose cotransporter 2 inhibitors, include the brand name drugs Invokana and Invokana (which contain the active ingredient canagliflozin); Farxiga and Xigduo XR (which contain the active ingredient dapagliflozin); and Jardiance (which contains the active ingredient empagliflozin). SGLT2 inhibitors lower blood sugar by causing the kidneys to remove the sugar from ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.